During the past decade, Centre François Magendie conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 1 clinical trials were completed, i.e. on average, 3.8% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 1 clinical trials were completed. i.e. 10% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre François Magendie" #1 sponsor was "The Lymphoma Academic Research Organisation" with 16 trials, followed by "Janssen Research & Development, LLC" with 4 trials sponsored, "Intergroupe Francophone du Myelome" with 3 trials sponsored, "Bayer" with 2 trials sponsored and "Celgene Corporation" with 2 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre François Magendie" #1 collaborator was "Bristol-Myers Squibb" with 2 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "Celgene" with 1 trials as a collaborator, "Fondation ARC" with 1 trials as a collaborator and "GFPC" with 1 trials as a collaborator. Other collaborators include 14 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Centre François Magendie" are "Acute Myeloid Leukemia" (3 trials), "B-cell Lymphoma" (2 trials), "Hodgkin Lymphoma" (2 trials), "Lymphoma, Non-Hodgkin" (2 trials) and "Multiple Myeloma" (2 trials). Many other conditions were trialed in "Centre François Magendie" in a lesser frequency.

Most popular intervention types in "Centre François Magendie" are "Drug" (31 trials), "Procedure" (4 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Gemcitabine" (5 trials), "Bendamustine" (3 trials), "Daratumumab" (3 trials), "Doxorubicin" (3 trials) and "Rituximab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Centre François Magendie" are 35 trials for "All" genders.

Currently, there are NaN active trials in "Centre François Magendie". undefined are not yet recruiting, 10 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Centre François Magendie, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Centre François Magendie, 5 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".